ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

ImmunityBio, Inc.NASDAQ: IBRX

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses remains negative

Q3 FY2026 other income / expenses was -$106.58M, compared with -$11.68M a year earlier. Trailing-twelve-month other income / expenses was -$835.68M.

Context

  • Other income / expenses amounted to 84.4% of revenue in FY2025, down 386.7 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$106.58M or moves back toward the trailing-twelve-month quarterly average of -$208.92M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$106.58M+36.8% QoQ
Last fiscal yearDec 2025
-$95.58M-37.6% YoY
LTMSep 2026
-$835.68M-850.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-812.6%——
1 year-37.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(95.58M) USD
Year-over-year change
-37.6%

Other Income / Expenses vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -850.2% is the lowest of 11, against a peer median of -34.5%.
  • Other income / expenses amounts to 457.7% of revenue for IBRX, versus a peer median of 7.5%.
IBRX Competitors
Other Income / Expenses for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€260.88M EUR-46.5%—9.9%
MRNAModerna, Inc.LTM Sep 2026$201M USD-35.2%+25.4%8.0%
IMCRImmunocore Holdings plcLTM Mar 2026$21.54M USD-13.2%+29.7%5.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M USD-3.2%——
NKTXNkarta, Inc.LTM Mar 2026$16.38M USD-21.0%+49.6%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$8.6M USD-33.8%+20.0%2.3%
LEGNLegend Biotech CorporationLTM Sep 2026-$1.9M USD+94.1%—0.1%
IMTXImmatics N.V.LTM Mar 2026-€2.64M EUR-106.2%—7.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$3.13M USD-36.7%—13.5%
IBRXImmunityBio, Inc.LTM Sep 2026-$835.68M USD-850.2%—457.7%
Peer median (excluding IBRX) —-34.5%+27.6%7.5%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.